Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR
- DOI
- 10.1038/s41591-025-04117-4
- Record issued
- 2026-08-10
- Engine
- 7.29.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/be014962-f4f0-4ba2-af46-4599f597f341 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern−0.5★
- ClaimsOverstated claim−0.5★
- ReportingData & code availability partially met−0.25★
- References were found (36) but none could be checked — every lookup failed or lacked a DOI.
- No reported statistical tests were found to recompute.
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.
- 01Internal contradictions in the reported numbers
The reported 1.49-fold accumulation in drug exposure does not match the Cmax and AUC values given in the same paragraph.
At week 1, mean C max was 26.1 ng ml −1 and AUC 0–168h was 1,880 h ng ml −1 , whereas at week 17, mean C max increased to 45.3 ng ml −1 and AUC 0–168h to 3,190 h ng ml −1 . The drug’s accumulation... showed a 1.49-fold increase in exposure for both parameters.
Resultsreviewer’s wording - 02Conclusion reaches beyond the evidence
The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.
“The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.”
ResultsFind in source
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and transparently reported phase 2b trial of branaplam in Huntington's disease, with strong scientific premise, robust design, and thorough ethical and reporting practices. The main weaknesses are minor reporting gaps: effect sizes are reported with SEs rather than CIs, the bespoke PK-PD modeling code is not shared, and several copyedit issues (unit inconsistencies, broken cross-references, typos) need correction.
This synthesis is based on two independent reviewer runs that largely agreed, with a divergence on data code availability (pass vs. warn) that was resolved by weighing the evidence for the missing PK-PD code. The statistics verification component could only recompute a subset of reported tests (none with test statistics/CIs), so the absence of detected errors does not confirm overall statistical correctness. The citation component found no retracted or unresolved references.
Numerical inconsistencies
1 finding · worst mediumValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
- mediuminternal contradictionThe reported 1.49-fold accumulation in drug exposure does not match the Cmax and AUC values given in the same paragraph.
At week 1, mean C max was 26.1 ng ml −1 and AUC 0–168h was 1,880 h ng ml −1 , whereas at week 17, mean C max increased to 45.3 ng ml −1 and AUC 0–168h to 3,190 h ng ml −1 . The drug’s accumulation... showed a 1.49-fold increase in exposure for both parameters.
Resultsreviewer’s wording
Overstated conclusions
1 finding · worst mediumConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions overstated beyond the evidenceAssessed
4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
- overstatedReviewer 1The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.The paper shows mHTT lowering of 25.2%, but clinical benefit was not demonstrated; the claim that this is the minimum expected to offer clinical benefits is based on modeling assumptions, not direct clinical outcomes.Evidence: Results, Modeling data leading to study termination: 'The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.'
“The 56 mg dose administered once weekly achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits.”
ResultsFind in source - supportedReviewer 1Branaplam is the first splicing modulator to lower mutant HTT levels in the cerebrospinal fluid of individuals with HD.The paper presents direct evidence of a 25.2% placebo-corrected lowering of CSF mHTT, supporting the claim that it lowers mHTT; the 'first' aspect is a novelty claim consistent with the presented data.Evidence: Results, Measured mHTT protein levels: 'At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81)'
“making branaplam the first splicing modulator to lower mutant HTT levels in the cerebrospinal fluid of individuals with HD”
AbstractFind in source - supportedReviewer 1Increased neurofilament light chain levels observed in most participants reversed after treatment discontinuation.The paper reports that all participants with follow-up data showed reversal of serum NfL increases, and similar reversal in NHP studies.Evidence: Results, Neurofilament light chain: 'At the end of the study, all participants with follow-up data showed reversal of the increase in serum NfL levels'
“At the end of the study, all participants with follow-up data showed reversal of the increase in serum NfL levels”
ResultsFind in source - supportedReviewer 1The results demonstrate that an oral HTT mRNA splice modulator can lower mHTT levels in the CSF of people with HD.The primary endpoint, though descriptive, shows a placebo-corrected reduction in CSF mHTT, directly supporting this claim.Evidence: Results, Measured mHTT protein levels: 'At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81)'
“The results of the VIBRANT-HD clinical trial demonstrate that an oral HTT mRNA splice modulator can lower mHTT levels in the CSF of people with HD.”
DiscussionFind in source
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
Prior work on HTT lowering and branaplam's mechanism is extensively cited (references 1–22). The rationale linking HTT lowering to disease modification is explicit, and the paper acknowledges limitations of prior safety observations (e.g., neurotoxicity in dogs) and addresses them through monitoring and study design.
“Branaplam had been shown to lower mHTT levels in neuroblastoma cells of individuals with HD and in an HD mouse model (BacHD)”
“Safety studies of branaplam in dogs identified a potential risk of neurotoxicity, as evidenced by axonal degeneration of peripheral nerves and spinal cord”
“This study aimed to identify a safe and well-tolerated oral dose of branaplam administered weekly that would lower CSF mHTT levels sufficiently to expect a clinical benefit.”
Randomization was by Interactive Response Technology at the participant level, and the study is described as double-blind and placebo-controlled. The sample size calculation used MCP-Mod, assumed 35% mHTT lowering at the highest dose, applied a 50% SD inflation factor, and targeted more than 80% power at a one-sided 5% alpha. Inclusion criteria, an age cap, and the safety analysis set (all participants receiving at least one dose) are defined. Because the trial terminated early after cohort 1, planned inferential analyses were replaced by descriptive summaries, which the paper discloses.
“All eligible participants were randomized via Interactive Response Technology to one of the treatment arms.”
“n = 75 for three dose arms (three active treatment groups with n = 20 in each arm and a placebo group with n = 15) was sufficient to reach more than 80% power on average for detecting a dose–response signal using multiple comparison procedures-modeling (MCP-Mod) methodology (under the MCP step) with a one-sided significance level of 5%.”
“All eligible participants were randomized via Interactive Response Technology to one of the treatment arms.”
“VIBRANT-HD was designed as a randomized, double-blind, placebo-controlled study”
“n = 75 for three dose arms (three active treatment groups with n = 20 in each arm and a placebo group with n = 15) was sufficient to reach more than 80% power on average for detecting a dose–response signal using multiple comparison procedures-modeling (MCP-Mod) methodology (under the MCP step) with a one-sided significance level of 5%.”
Sex is stated as 'male and female participants' and age range is given. Health status (HD stage, TFC score) is reported. Demographics are partially reported: age, sex, disease stage are present, but race/ethnicity and comorbidities are not explicitly listed in the text (though baseline table may include more). This is a minor gap.
“The study population included male and female participants aged >25 years”
“An age cap of 75 years was used to avoid age-related comorbidities”
“The study population included male and female participants aged >25 years with confirmed stage 1 or 2 HD”
“At dosing initiation, the monkeys were approximately 31–38 months of age and weighed 2.1–3.0 kg.”
The protocol was approved by multiple named institutional review boards/ethics committees. Written informed consent was obtained from each participant. The study was conducted according to ICH E6 and the Declaration of Helsinki. All applicable sub-criteria are adequate.
“Informed consent was obtained from each participant in writing before screening and before any study-specific procedure was performed.”
“The VIBRANT-HD study was conducted according to ICH E6 Guidelines for Good Clinical Practice that have their origin in the Declaration of Helsinki.”
“The study protocol was reviewed and approved by institutional review boards and ethics committees at each participating site, including: Comité de Protection des Personnes Sud-Ouest et Outre-Mer II (Toulouse, France); Ethikkommission der Universität Ulm (Ulm, Germany);”
“Informed consent was obtained from each participant in writing before screening and before any study-specific procedure was performed.”
“All procedures in the 6-week and 39-week studies were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, the Office of Laboratory Animal Welfare, and fully commensurate with international standards of Good Laboratory Practices and approved by the local Institutional Animal Care and Use Committee.”
Branaplam is identified as the drug with manufacturer (Novartis) and formulation (oral solution). The NfL assay kit is specified (Simoa NF-light Advantage Kit, cat. no. 103400). NHP species and sources are given. Software versions are stated (SAS v.9.4, Monolix v.2018r1, RStudio v.3.6.1). Antibodies, cell lines, and mycoplasma testing are not applicable.
“starting with branaplam 56 mg oral solution or matching placebo once weekly”
“using a qualified single-molecule array immunoassay according to the manufacturer’s instructions (Simoa NF-light Advantage Kit for SR-X; cat. no. 103400, Quanterix)”
“cynomolgus monkeys ( Macaca fascicularis ) obtained from Envigo Global Services Inc.”
“branaplam 56 mg oral solution or matching placebo once weekly”
“(Simoa NF-light Advantage Kit for SR-X; cat. no. 103400, Quanterix)”
“SAS v.9.4 (SPSS) and higher was used for the analyses.”
The study was terminated early and reported descriptively; no hypothesis tests or p-values were computed, so exact_p_values and assumptions_verified are not applicable. Effect sizes (mean differences) are reported with SEs, not CIs, which is a minor gap. Software is named (SAS v.9.4). Data presentation is good (spaghetti plots, individual NfL plots, per-group n). Arithmetic checks on percentages and the placebo-corrected difference are consistent.
“At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81)”
“SAS v.9.4 (SPSS) and higher was used for the analyses.”
“Individual serum and CSF levels of NfL over time.”
“Because the early termination of the trial (‘Results’) led to a small sample size, the primary endpoint of mHTT in CSF was summarized descriptively based on the safety analysis set.”
“At week 17, the difference in mean percentage (s.e.) change (branaplam 56 mg to placebo) was −25.2% (−2.81)”
“All analyses were performed on the safety analysis set of the first cohort, which consists of all participants who received at least one dose of study drug over the core period.”
The reader is directed to CSDR with a data-sharing agreement and independent review panel, and protocol/SAP PDFs are posted on ClinicalTrials.gov, satisfying the availability statement and clinical data-access criteria. Patient-level data are legitimately managed-access, so an open repository deposit is not applicable. No statement describes availability of the custom PK–PD simulation code used for the termination decision.
“The reader is able to request the raw data (anonymized) and related documents (for example, clinical study report) of the clinical study by connecting to CSDR ( https://www.clinicalstudydatarequest.com ) and signing a Data Sharing Agreement with Novartis.”
“Protocol and SAP are available on ClinicaltTrials.gov at https://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/Prot_000.pdf and https://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/SAP_001.pdf , respectively.”
The trial is registered with a ClinicalTrials.gov identifier, and protocol/SAP links are provided. A CONSORT diagram (Extended Data Fig. 1) and a Nature Portfolio Reporting Summary accompany the manuscript. Null results (UHDRS, cognitive measures, whole-brain/caudate volumes) are reported transparently, and the limitations of the placebo-arm imbalance and absent CSF NfL follow-up are discussed. Funding (Novartis) and detailed competing-interest disclosures are provided. The main conclusions are appropriately hedged to descriptive, small-sample evidence.
“ClinicalTrials.gov identifier: NCT05111249”
“As a limitation, following the early termination of the VIBRANT-HD trial, the number of participants in the placebo arm was one-quarter of that in the branaplam arm”
“ClinicalTrials.gov identifier: NCT05111249”
“As a limitation, following the early termination of the VIBRANT-HD trial, the number of participants in the placebo arm was one-quarter of that in the branaplam arm”
“The study was funded by Novartis.”
Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 36 references by DOI: 0 verified — 36 no DOI (shown, not verified).
- NO DOIHuntington disease: natural history, biomarkers and prospects for therapeutics.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntington’s disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin and its partner Huntingtin-Associated Protein 40: structural and functional considerations in health and disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe biology of huntingtin.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPolyglutamine diseases: emerging concepts in pathogenesis and therapy.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntington’s disease: from molecular pathogenesis to clinical treatment.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin and its role in mechanisms of RNA-mediated toxicity.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITherapeutic approaches to Huntington disease: from the bench to the clinic.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITargeting RNA structures with small molecules.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAn alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington’s disease patient neurons.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAn orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITherapeutic update on Huntington’s disease: symptomatic treatments and emerging disease-modifying therapies.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin lowering strategies for disease modification in Huntington’s disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntingtin-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risks.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUltrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITargeting huntingtin expression in patients with Huntington’s disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDiverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINeurofilament light chain: a translational safety biomarker for drug-induced peripheral neurotoxicity.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIOrally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogs.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIInsights into the human pharmacokinetics and metabolism of branaplam, a splicing modulator of a survival motor neuron-2 ( SMN2 ) and huntingtin ( HTT ) pre-MRNAs, in infants and adults.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBranaplam translational PK/PD model supported key decision making in Huntington’s disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPredictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPrimary cilia and autophagic dysfunction in Huntington’s disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA novel function of huntingtin in the cilium and retinal ciliopathy in Huntington’s disease mice.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITominersen in adults with manifest Huntington’s disease.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOII010 RNA splicing modulator for Huntington’s disease treatment induces 1 peripheral neuropathy.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRNA splicing modulator for Huntington's disease treatment induces peripheral neuropathy.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISTP position paper: recommended practices for sampling and processing the nervous system (brain, spinalcord, nerve, and eye) during nonclinical general toxicity studies.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHuntington disease: clinical care and evaluation.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUnified Huntington’s Disease Rating Scale: reliability and consistency.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMotor, cognitive, and functional declines contribute to a single progressive factor in early HD.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIIdentification of brain disorders by the Stroop Color and Word Test.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISymbol Digit Modalities TestNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
5 data/code links checked; 5 live.
- datahttps://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/Prot_000.pdfLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://cdn.clinicaltrials.gov/large-docs/49/NCT05111249/SAP_001.pdfLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://www.clinicalstudydatarequest.comLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT05111249?term=NCT05111249LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT02268552LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
1 finding · worst lowWording, consistency and formatting errors that need correcting before submission.
- Wording or formatting errors that need correctingAssessed
11 copyedit issues flagged (2 major): mostly consistency, typo, other.
- MAJORconsistencyFig. 4 legend“Values above 500 mg ml −1 are imputed to 501 pg ml −1”→ Correct the unit to 'pg ml−1' in both placesUnit inconsistency: mg vs pg.
- MAJORconsistencyResults, Pharmacokinetics“showed a 1.49-fold increase in exposure for both parameters”→ Recalculate the ratio from the reported Cmax and AUC valuesCmax ratio (45.3/26.1) is 1.74, AUC ratio (3190/1880) is 1.70; 1.49 is inconsistent.
- MINORtypoData Availability Statement“ClinicaltTrials.gov”→ Change to 'ClinicalTrials.gov'Double 't' typo.
- MINORconsistencyDiscussion, paragraph 3“S. Jetvic”→ Change to 'S. Jevtic' to match earlier spellingInconsistent author name spelling.
- MINORconsistencyResults, Histopathology“see Supplementary Tables and for more details”→ Insert the table numbers (e.g., Supplementary Tables 1 and 2)Missing table numbers.
- MINORconsistencyResults, Neurofilament light chain“76.2% and 61.9% of the participants in the active arm had an increase in serum NfL and CSF NfL levels”→ Clarify how the abstract's 71.4% relates to these percentagesPotential inconsistency in reported NfL elevation rates.
- MINORconsistencyMethods, Statistical analysis“SAS v.9.4 (SPSS) and higher was used for the analyses.”→ Use 'SAS v.9.4 (SAS Institute Inc.) or later' — SAS and SPSS are distinct software packages.The parenthetical '(SPSS)' appears to be an editing artifact.
- MINORconsistencyFig. 4a caption“Values above 500 mg ml −1 are imputed to 501 pg ml −1 for the purpose of analysis.”→ Change '500 mg ml −1' to '500 pg ml −1' to match the assay range stated earlier in the same caption.Unit mismatch mg vs pg.
- MINORtypoData availability statement / Online content“ClinicaltTrials.gov”→ ClinicalTrials.govExtra 't'.
- MINORotherMethods, Study endpoints and assessments“The protein assay used to measure mHTT is described in the .”→ Insert the cross-reference (e.g., 'described in the Supplementary Methods').Broken cross-reference — blank target.
- MINORotherMethods, VIBRANT-HD Study design“More details on treatment, randomization and blinding are provided in the .”→ Insert the cross-reference target or remove the sentence.Broken cross-reference.
The published work is methodologically robust and transparent, but an informed reader should weigh the missing PK-PD code sharing and the lack of confidence intervals for key effect estimates. The internal contradiction in the PK accumulation ratio (1.49 vs. 1.74/1.70) and the unit inconsistency in Fig. 4 warrant an erratum or correction. The overstated claim about clinical benefit should be tempered in any future communication.
- 1.HIGHstatisticsRecalculate and correct the PK accumulation ratio in Results, Pharmacokinetics: the reported 1.49-fold increase does not match the Cmax ratio (45.3/26.1 = 1.74) or AUC ratio (3190/1880 = 1.70).This is an internal contradiction that undermines the accuracy of the pharmacokinetic results and could mislead readers.
- 2.HIGHcopyeditFix the unit inconsistency in Fig. 4 legend and caption: change '500 mg ml−1' to '500 pg ml−1' in both places.A unit error in a figure legend is a factual error that could be misinterpreted and is a clear copyedit defect.
- 3.HIGHdata codePublish the translational PK-PD model simulation scripts/code in a public repository (e.g., Zenodo/GitHub) with a permanent identifier and cite it in the Data Availability statement.The PK-PD model underpins the dose-simulation analysis supporting the termination decision; without the code, the analysis is not reproducible.
- 4.HIGHstatisticsAdd 95% confidence intervals for the mean percentage changes and the placebo-corrected difference at weeks 9 and 17 in Results, 'Measured mHTT protein levels'.Reporting only standard errors does not convey the precision of the effect estimates, which is a key statistical reporting gap.
- 5.HIGHreportingTemper the claim that the 56 mg dose 'achieved the minimum reduction in mHTT levels that is expected to offer clinical benefits' to reflect that clinical benefit was not demonstrated and this is based on modeling assumptions.The claim audit flagged this as overstated; over-claiming clinical benefit from a biomarker endpoint is a common reviewer objection.
- 6.MEDIUMcopyeditRepair the broken cross-references in Methods: 'described in the .' (CSF mHTT assay) and 'provided in the .' (treatment/randomization details) by inserting the correct supplementary section or table numbers.Broken cross-references prevent readers from locating essential methodological details.
- 7.MEDIUMcopyeditCorrect the typo 'ClinicaltTrials.gov' to 'ClinicalTrials.gov' in the Data Availability Statement and Online content.A misspelled registry name is a simple but visible error that should be fixed.
- 8.MEDIUMcopyeditFix the inconsistent author name spelling 'S. Jetvic' to 'S. Jevtic' in the Discussion.Inconsistent author name spelling is a copyedit error that should be corrected for consistency.
- 9.MEDIUMcopyeditInsert the missing supplementary table numbers in Results, Histopathology: 'see Supplementary Tables and' should specify the table numbers.Missing table numbers prevent readers from locating the histopathology data.
- 10.MEDIUMreportingClarify the relationship between the abstract's 71.4% NfL elevation and the Results' 76.2% serum and 61.9% CSF percentages, or unify the definitions.The apparent inconsistency in reported NfL elevation rates could confuse readers and needs reconciliation.
- 11.MEDIUMotherAdd a sentence in Methods 'NHP studies' describing housing/husbandry conditions (light/dark cycle, temperature, enrichment) for the 6- and 39-week cynomolgus monkey studies.Housing conditions are a standard reporting requirement for animal studies and are currently missing.
- 12.MEDIUMotherState the rationale for the all-male 6-week NHP dose-range-finding study, or cite the convention for early toxicology screens.The lack of sex justification for the NHP study is a minor but addressable reporting gap.
- 13.LOWcopyeditCorrect the parenthetical in Methods, Statistical analysis: 'SAS v.9.4 (SPSS)' should be 'SAS v.9.4 (SAS Institute Inc.)' or similar, as SAS and SPSS are distinct software packages.The current phrasing appears to be an editing artifact that could confuse readers about the software used.
- 14.LOWreportingState explicitly in Methods 'Statistical analysis' that no inferential statistical tests were performed due to early termination, and that all results are descriptive.This preempts confusion about missing p-values and clarifies the exploratory nature of the results.
- 15.LOWotherState the planned randomization allocation ratio among the three dose arms and placebo (implied 20:20:20:15) in Methods 'Statistical analysis'.Explicitly stating the allocation ratio aids interpretation of the realized 21:5 split and the study's design.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.